CPSF3 and cancer: Since CPSF3 expression is also negatively affected by both PladB and THZ531 treatment (Fig. 6D, Additional File 2: Fig. S8H,I), these findings suggest that 22Rv1 cells particularly rely on these two 3’-end processing factors and that their repression could contribute to the anti-cancer activity of splicing-targeting drugs.